Selected Publications
Books
Novel anti-HIV-1 agents in development,pp.719-725 (Co-authored) 2023/03
Papers
An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier PNAS Nexus (Co-authored) 2025/01
Papers
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants Science Advances (Co-authored) 2023/07/12
Papers
Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2 Nature Communications (Co-authored) 2023
Papers
Design, Synthesis and X-Ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing C-4 Substituted Tricyclic Hexahydro-Furofuran Derivatives as P2 Ligands. ChemMedChem (Co-authored) 2022
Papers
Single atom changes in newly synthesized HIV protease inhibitors reveal structural basis for extreme affinity, high genetic barrier, and adaptation to the HIV protease plasticity. Scientific Reports (Co-authored) 2020
Papers
A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Global Health & Medicine 1,pp.36--48 (Co-authored) 2019
Papers
Novel protease inhibitors containing C-5-modified bis-THF and aminobenzothiazole as P2 and P2' ligands that exert potent antiviral activity against highly multidrug-resistant HIV-1 with high genetic barrier against the emergence of drug resistance. Antimicrobial Agents and Chemotherapy 25 (63(8)),pp.e00372--19 (Co-authored) 2019
Papers
Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance. 6 (9(2)),pp.e02425--17 (Co-authored) 2018
Papers
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. eLife 17 (6),pp.e28020 (Co-authored) 2017
Papers
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir. Jornal of Virology 18 (90(5)),pp.01829--15 (Co-authored) 2015